These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35769471)

  • 1. Corrigendum: Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.
    Carascal MB; Pavon RDN; Rivera WL
    Front Immunol; 2022; 13():948031. PubMed ID: 35769471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines.
    Sridhar S
    Front Immunol; 2016; 7():195. PubMed ID: 27242800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice.
    Liu Q; Xue C; Zheng J; Liu K; Wang Y; Wei Y; Liu GD; Cao Y
    Vaccine; 2015 Jul; 33(32):4035-40. PubMed ID: 26100927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children.
    Steinhoff MC; Fries LF; Karron RA; Clements ML; Murphy BR
    J Clin Microbiol; 1993 Apr; 31(4):836-8. PubMed ID: 8463393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum: Mucosal and Systemic Immune Responses to Influenza H7N9 Antigen HA1-2 Co-Delivered Intranasally With Flagellin or Polyethyleneimine in Mice and Chickens.
    Song L; Xiong D; Song H; Wu L; Zhang M; Kang X; Pan Z; Jiao X
    Front Immunol; 2018; 9():1846. PubMed ID: 30131811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection.
    Valkenburg SA; Li OT; Mak PW; Mok CK; Nicholls JM; Guan Y; Waldmann TA; Peiris JS; Perera LP; Poon LL
    Proc Natl Acad Sci U S A; 2014 Apr; 111(15):5676-81. PubMed ID: 24706798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-sterilizing, Infection-Permissive Vaccination With Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective Heterosubtypic Immunity From Cellular to Humoral Cross-Reactive Immune Responses.
    Choi A; Ibañez LI; Strohmeier S; Krammer F; García-Sastre A; Schotsaert M
    Front Immunol; 2020; 11():1166. PubMed ID: 32582220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.
    Ding H; Tsai C; Zhou F; Buchy P; Deubel V; Zhou P
    PLoS One; 2011 Mar; 6(3):e17821. PubMed ID: 21464977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum: Combining different bacteria in vaccine formulations enhances the chance for antiviral cross-reactive immunity: a detailed
    Bodas-Pinedo A; Lafuente EM; Pelaez-Prestel HF; Ras-Carmona A; Subiza JL; Reche PA
    Front Immunol; 2023; 14():1284628. PubMed ID: 37744348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration.
    Budimir N; de Haan A; Meijerhof T; Gostick E; Price DA; Huckriede A; Wilschut J
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1202-9. PubMed ID: 24102979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research progress and prospect of universal influenza vaccine].
    Luo DY; Xue CY; Cao YC
    Bing Du Xue Bao; 2013 Nov; 29(6):646-50. PubMed ID: 24520771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
    Dabaghian M; Latify AM; Tebianian M; Nili H; Ranjbar AR; Mirjalili A; Mohammadi M; Banihashemi R; Ebrahimi SM
    Vet Microbiol; 2014 Nov; 174(1-2):116-26. PubMed ID: 25293397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum: Bacillus Calmette-Guérin-Induced Trained Immunity Is Not Protective for Experimental Influenza A/Anhui/1/2013 (H7N9) Infection in Mice.
    de Bree LCJ; Marijnissen RJ; Kel JM; Rosendahl Huber SK; Aaby P; Benn CS; Wijnands MVW; Diavatopoulos DA; van Crevel R; Joosten LAB; Netea MG; Dulos J
    Front Immunol; 2018; 9():2471. PubMed ID: 30393473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines.
    Cheng X; Eisenbraun M; Xu Q; Zhou H; Kulkarni D; Subbarao K; Kemble G; Jin H
    PLoS One; 2009; 4(2):e4436. PubMed ID: 19209231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum: Induction of Robust B Cell Responses After Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells.
    Lindgren G; Ols S; Liang F; Thompson EA; Lin A; Hellgren F; Bahl K; John S; Yuzhakov O; Hassett KJ; Brito LA; Salter H; Ciaramella G; Loré K
    Front Immunol; 2019; 10():614. PubMed ID: 31001251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.
    Wohlbold TJ; Nachbagauer R; Xu H; Tan GS; Hirsh A; Brokstad KA; Cox RJ; Palese P; Krammer F
    mBio; 2015 Mar; 6(2):e02556. PubMed ID: 25759506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward a universal influenza virus vaccine: Some cytokines may fulfill the request.
    Taheri M; Nemattalab M; Mahjoob M; Hasan-Alizadeh E; Zamani N; Nikokar I; Evazalipour M; Soltani Tehrani B; Shenagari M
    Cytokine; 2021 Dec; 148():155703. PubMed ID: 34555604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum: Pediatric Burn Survivors Have Long-Term Immune Dysfunction With Diminished Vaccine Response.
    Johnson BZ; McAlister S; McGuire HM; Palanivelu V; Stevenson A; Richmond P; Palmer DJ; Metcalfe J; Prescott SL; Wood FM; Fazekas de St Groth B; Linden MD; Fear MW; Fear VS
    Front Immunol; 2020; 11():598646. PubMed ID: 33163008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.